CASIF — CASI Pharmaceuticals Share Price
Last trade - 00:00- $2.32m
- $16.49m
- $28.54m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -167.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.14 | 30.17 | 43.11 | 33.88 | 28.54 | 13.49 | n/a | 47.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Directors
- Wei-Wu He CHM (55)
- Wei Zhang PRE (62)
- Alexander Zukiwski OTH (63)
- James Huang IND (56)
- Franklin Salisbury IND (65)
- Rajesh Shrotriya IND (77)
- Y. Alexander Wu IND (57)
- Quan Zhou IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- January 10th, 2023
- Public Since
- August 23rd, 2021
- No. of Employees
- 233
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 15,492,681
- Address
- 1701-1702, China Central Office Tower 1,, BEIJING, 100025
- Web
- https://www.casipharmaceuticals.com/
- Phone
- +86 null1065618789
- Auditors
- KPMG Huazhen LLP
Upcoming Events for CASIF
Similar to CASIF
Acusphere
Pink Sheets on Nasdaq
Adaptimmune Therapeutics
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Allied
Pink Sheets on Nasdaq
FAQ
As of Today at 19:49 UTC, shares in CASI Pharmaceuticals are trading at $0.15. This share price information is delayed by 15 minutes.
Shares in CASI Pharmaceuticals last closed at $0.15 and the price had moved by -91.71% over the past 365 days. In terms of relative price strength the CASI Pharmaceuticals share price has underperformed the S&P500 Index by -93.45% over the past year.
The overall consensus recommendation for CASI Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCASI Pharmaceuticals does not currently pay a dividend.
CASI Pharmaceuticals does not currently pay a dividend.
CASI Pharmaceuticals does not currently pay a dividend.
To buy shares in CASI Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.15, shares in CASI Pharmaceuticals had a market capitalisation of $2.32m.
Here are the trading details for CASI Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CASIF
Based on an overall assessment of its quality, value and momentum CASI Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CASI Pharmaceuticals is $4.00. That is 2566.67% above the last closing price of $0.15.
Analysts covering CASI Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.58 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CASI Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -89.48%.
As of the last closing price of $0.15, shares in CASI Pharmaceuticals were trading -85.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CASI Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CASI Pharmaceuticals' management team is headed by:
- Wei-Wu He - CHM
- Wei Zhang - PRE
- Alexander Zukiwski - OTH
- James Huang - IND
- Franklin Salisbury - IND
- Rajesh Shrotriya - IND
- Y. Alexander Wu - IND
- Quan Zhou - IND